Home » Newsletters » BioWorld Science

BioWorld Science

Feb. 19, 2018

View Archived Issues

Moleculin Biotech and MD Anderson discover new STAT3 inhibitor

Japanese approval for Actair for children with house dust mite-induced allergic rhinitis

Novoheart and Sumocor enter agreement to develop therapeutics for heart failure

RCGD-423 prevents articular cartilage degeneration and promotes repair in vivo

FDA grants orphan drug designation to ProMetic's IaIp for necrotizing enterocolitis

Novel Toll-like receptor 2 antagonists discovered at Neuropore Therapies

FDA issues complete response letter for Vitaros

Bayer patents new menin/MLL interaction inhibitors

IOCB Prague and Palecky University Olomouc describe new anticancer nucleosides

Dosing begins in phase Ib study of MYK-491

Bristol-Myers Squibb identifies novel Toll-like receptor 7/8/9 antagonists

New NMDA NR2 receptor modulators synthesized at Aptinyx

CSIC, Centre Hospitalier Universitaire Vaudois present novel compounds for pancreatic cancer

Gilead Sciences' Harvoni approved for new indication in Japan

Phase I results for VRC-5288 and VRC-5283 Zika virus DNA vaccine candidates

Avillion opens IND for phase II study of Merck KGaA's M-1095

Wilson Therapeutics initiates phase III trial of WTX-101 for Wilson's disease

FDA approves Imfinzi for unresectable stage III NSCLC

Palbociclib shows limited activity in metastatic urothelial cancer trial

Sumitomo Dainippon Pharma, Intercept amend obeticholic acid agreement

Shire presents clinical data on SHP-647 for the treatment of Crohn's disease

Rapid remission seen in Crohn's disease patients treated with upadacitinib

Fluarix Tetra approved in Europe for use from 6 months of age

FDA grants orphan drug designation to Hansa's IdeS for Guillain-Barre syndrome

Galderma signs joint research agreement on atopic dermatitis with Icahn and Northwestern University

Cincera Therapeutics launches with aim of treating diseases associated with obesity

Great Point Partners expresses opposition to BioCryst's proposed merger with Idera

TRDN user survey - We want your opinion

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 18, 2025.
HIV research is close to a cure but far from ending the pandemic
BioWorld
Advances in antiretroviral therapy (ART) now allow people living with HIV to lead normal lives with undetectable and nontransmissible levels of the virus in their...
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 18, 2025.
Maintenance, man: Lilly’s phase III weight trial hits goals
BioWorld
Eli Lilly and Co. took another step toward adding a way for patients to hang onto their weight loss when the firm disclosed positive top-line data from the phase...
AI drug developer Insilico to raise $292 million in Hong Kong IPO
BioWorld
Insilico Medicine Inc. plans to raise HK$2.27 billion (US$292 million) in its IPO on the Hong Kong Securities Exchange to advance its clinical pipeline and invest...